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CGM

:   continuous glucose monitoring

DPV

:   Prospective Diabetes Follow‐Up Registry

HbA1c

:   hemoglobin A1c

T1DX

:   T1D Exchange Registry

1. INTRODUCTION {#pedi12711-sec-0005}
===============

The goal of diabetes management in children and adolescents with type 1 diabetes (T1D) is to achieve tight glycemic control to prevent acute and chronic complications; however, youth often fail to meet hemoglobin A1c (HbA1c) targets.[1](#pedi12711-bib-0001){ref-type="ref"}, [2](#pedi12711-bib-0002){ref-type="ref"} Growing evidence shows the benefit of continuous glucose monitoring (CGM) as a basis for improving glycemic control in those who wear the CGM device almost daily.[3](#pedi12711-bib-0003){ref-type="ref"}, [4](#pedi12711-bib-0004){ref-type="ref"}, [5](#pedi12711-bib-0005){ref-type="ref"}

Although the potential benefits of CGM are well known to clinicians, the actual rates of CGM device use in T1D youth in prior studies have been low. In an earlier study of the T1D Exchange Registry (T1DX), only 6% of children \<13 years and 4% of adolescents 13 to \<18 years were using CGM.[6](#pedi12711-bib-0006){ref-type="ref"} Previously, DPV (Prospective Diabetes Follow‐Up Registry) data were used to compare pump and injection users.[7](#pedi12711-bib-0007){ref-type="ref"} In the DPV registry, rates of CGM use were even lower; however, reimbursement by health insurance for CGM in Germany and Austria recently started in summer of 2016. The JDRF (Juvenile Diabetes Research Foundation International) CGM randomized controlled trial published in 2008[3](#pedi12711-bib-0003){ref-type="ref"} highlighted the challenge of CGM use in adolescents and young adults. After 6 months, only 30% of the adolescents and young adults (15‐24 years) were using CGM 6 or more days per week compared to 83% of adults aged 25 years or older. However, among those who were using CGM on a daily or near‐daily basis, improvement in glycemic control was similar, independent of age group.

Over the past 10 years, the accuracy[8](#pedi12711-bib-0008){ref-type="ref"} and usability of CGM devices has improved considerably, which may be accompanied by an increase in CGM use, and associated improvement in glycemic control. To assess this, we analyzed data from the US T1DX and German/Austrian DPV registries to assess the increase in CGM use over the past 5 years, compare current CGM use between registries, and compare glycemic control (HbA1c %) between current CGM users and non‐users.

2. METHODS {#pedi12711-sec-0006}
==========

We analyzed T1DX Registry and DPV Initiative participants aged \<18 years with T1D duration ≥1 year in 2011 and again in 2016. This encompassed 29 007 individuals in 2011 (*N* = 11 608 from T1DX and *N* = 17 399 from DPV) and 29 150 participants in 2016 (*N* = 8186 from 72 T1DX sites and *N* = 20 964 from 309 DPV sites). Demographic data, CGM use (either real‐time or intermittent "flash" CGM), insulin modality (injections or insulin pump) and the most recent HbA1c value were obtained from clinic medical records. Definitions of migration background or ethnic minority status for each registry were as described previously[9](#pedi12711-bib-0009){ref-type="ref"} (DPV: patient or at least one parent born outside of Austria/Germany, T1DX: any race/ethnicity other than non‐Hispanic white). Sites for the DPV and T1DX are listed in [S1](#pedi12711-supitem-0001){ref-type="supplementary-material"} (Supporting Information).

Logistic and linear regression modeling were used to compare demographic and clinical characteristics in 2011 vs 2016 within each registry. Differences in CGM use between registries was assessed separately for 2011 and 2016 time points in a logistic regression model stratified by age group and adjusted for gender, minority status and diabetes duration. The interaction between CGM use and registry on mean HbA1c in 2016 was assessed in a linear regression model adjusted for age, gender, and minority status. Separate statistical tests were performed comparing T1DX vs DPV in CGM users and non‐users for each age group. The interaction between insulin delivery method and CGM use on mean HbA1c within each registry was assessed in linear regression models adjusted for age, gender and minority status. All statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, North Carolina). All *P‐*values are two‐sided. A priori, in view of the large sample size and multiple comparisons, only *P*‐values \<0.01 were considered statistically significant.

3. RESULTS {#pedi12711-sec-0007}
==========

Demographic and clinical characteristics for both T1DX and DPV registries in 2011 vs 2016 are displayed in Table [1](#pedi12711-tbl-0001){ref-type="table"}. In the last 5 years, CGM use increased from 4% to 19% for the DPV Initiative (*P* \< 0.001) and from 3% to 22% in the T1DX Registry (*P* \< 0.001). CGM use increased for all age groups in both registries, and was most pronounced in the youngest patients (1 to \<6 years) with an increase from 6% to 28% for DPV and 4% to 45% for T1DX. Although CGM use increased significantly from 2011, adolescent patients (13 to \<18 years) had the lowest rates of CGM use in 2016 (DPV: 3% in 2011, 16% in 2016; T1DX: 3% in 2011, 17% in 2016). For both registries, CGM use increased from 2011 to 2016 regardless of gender or ethnic minority status, as well as for both pump and injection users. Notably, insulin pump use increased for both T1DX and DPV registries between 2011 and 2016, with usage rates exceeding 50% in DPV and 60% in T1DX in 2016.

###### 

Participant characteristics and diabetes management data in 2011 vs 2016 for each registry

                                                             DPV                   *P*‐value             T1DX      *P*‐value                                   
  ---------------------------------------------------------- --------------------- --------------------- --------- --------------------- --------------------- ---------
  Gender (male)                                              52%                   52%                   0.6       51%                   52%                   0.4
  Age (y), mean ± SD                                         12 ± 4                12 ± 4                \<0.001   12 ± 4                13 ± 4                \<0.001
  \<6                                                        6%                    5%                              6%                    5%                    
  6 to \<13                                                  34%                   32%                             46%                   37%                   
  13 to \<18                                                 60%                   64%                             48%                   58%                   
  Duration of diabetes (y), mean ± SD                        5 ± 3                 5 ± 3                 \<0.001   5 ± 4                 7 ± 4                 \<0.001
  HbA1c, % (mmol/mol), mean ± SD                             7.9 ± 1.4 (63 ± 15)   7.8 ± 1.3 (62 ± 14)   \<0.001   8.5 ± 1.5 (70 ± 16)   8.8 ± 1.6 (72 ± 18)   \<0.001
  Percentage of subjects with HbA1c \<7.5% (\<58 mmol/mol)   43%                   46%                   \<0.001   22%                   19%                   \<0.001
  Ethnic minority status                                     20%                   23%                   \<0.001   22%                   22%                   0.8
  Pump use                                                   43%                   56%                   \<0.001   56%                   64%                   \<0.001
  Overall CGM use                                            4%                    19%                   \<0.001   3%                    22%                   \<0.001
  CGM use by age (y)                                                                                                                                           
  \<6                                                        6%                    28%                   \<0.001   4%                    45%                   \<0.001
  6 to \<12                                                  4%                    23%                   \<0.001   4%                    27%                   \<0.001
  12 to \<18                                                 3%                    16%                   \<0.001   3%                    17%                   \<0.001
  CGM use by gender                                                                                                                                            
  Male                                                       4%                    18%                   \<0.001   3%                    21%                   \<0.001
  Female                                                     4%                    19%                   \<0.001   3%                    22%                   \<0.001
  CGM use by ethnicity                                                                                                                                         
  Minority status: yes                                       3%                    14%                   \<0.001   2%                    12%                   \<0.001
  Minority status: no                                        4%                    20%                   \<0.001   4%                    25%                   \<0.001
  CGM use by insulin delivery method                                                                                                                           
  Injections                                                 3%                    14%                   \<0.001   1%                    9%                    \<0.001
  Pump                                                       5%                    22%                   \<0.001   5%                    29%                   \<0.001

After adjustment for gender, ethnic/minority status and diabetes duration, CGM use was similar between registries in 2011 for patients aged 1 to \<6 years (*P* = 0.20) and 6 to \<12 years (*P* = 0.94) with higher CGM use in T1DX compared to DPV for 12 to \<18 years (*P* = 0.005). In 2016, higher CGM use was observed in T1DX compared with DPV among 1 to \<6 and 6 to \<13 years (both adjusted *P* \< 0.001). There were no significant differences in CGM use between registries for 13 to \<18‐year‐old age groups (adjusted *P* = 0.15).

In 2011, CGM use was not associated with a difference in HbA1c among DPV participants (7.9% vs 7.9% \[63 vs 63 mmol/mol\], *P* = 0.55); however, in 2016 mean HbA1c was lower in CGM users (7.6% vs 7.9% \[60 vs 63 mmol/mol\], *P* \< 0.001). For T1DX CGM users, lower mean HbA1c compared to non‐users was seen in both 2011 (7.9% vs 8.6% \[63 vs 70 mmol/mol\], *P* \< 0.001) and 2016 (8.1% vs 9.0% \[65 vs 75 mmol/mol\], *P* \< 0.001).

Mean HbA1c in DPV vs T1DX according to CGM use and age group for the more recent 2016 data is shown in Figure [1](#pedi12711-fig-0001){ref-type="fig"}. T1DX participants had a higher mean HbA1c compared with DPV despite whether they were CGM users or non‐users. However, the difference between mean HbA1c in DPV vs T1DX was less pronounced in CGM users (*P* \< 0.001) (Figure [1](#pedi12711-fig-0001){ref-type="fig"}). In 2016, mean HbA1c was lower among CGM users regardless of insulin delivery method compared to pump only (*P* \< 0.001) and injection only (*P* \< 0.001) in both T1DX and DPV registries (Figure [1](#pedi12711-fig-0001){ref-type="fig"}B). Additionally, CGM users were more likely to achieve glycemic targets (HbA1c \< 7.5% \[\<58 mmol/mol\]) for both DPV (56% vs 43%, *P* \< 0.001) and T1DX (30% vs 15%, *P* \< 0.001) registries in 2016.

![(A) Mean HbA1c in 2016 for each registry stratified by CGM use and age group. Solid black bar represents CGM users. Solid white bar represents non‐CGM users. (B) Mean HbA1c by insulin delivery method and CGM use within each registry in 2016. BGM, blood glucose monitoring; CGM, continuous glucose monitoring or intermittent flash glucose monitoring. \**P*‐values compared with the reference group of pump + CGM](PEDI-19-1271-g001){#pedi12711-fig-0001}

4. DISCUSSION {#pedi12711-sec-0008}
=============

Utilization of CGM in pediatric T1D management provides opportunity to improve glycemic control if consistent CGM use can be achieved in this population. In this study, CGM use was associated with lower mean HbA1c across all ages and regardless of insulin delivery modality for both registries. Additionally, a higher percentage of CGM users compared to non‐users achieved a glycemic target of \<7.5% (\<58 mmol/mol) in both registries. The cross‐sectional nature of our study does not preclude the possibility that those with lower HbA1c were more likely to initiate CGM; however, our findings align with results from controlled trials showing improved glycemic control with CGM use compared to SMBG only.[3](#pedi12711-bib-0003){ref-type="ref"}, [4](#pedi12711-bib-0004){ref-type="ref"}, [5](#pedi12711-bib-0005){ref-type="ref"} Other limitations to our study include: data on CGM brand and consistency of use by patients were not available, and we did not differentiate between real‐time CGM vs flash glucose monitoring in this analysis. Additionally, the difference in ethnic minority definitions between the DPV and T1DX Registries limits the ability to compare across continents.

Improvement in CGM technology over the last 10 years, as well as growing evidence for clinical efficacy of CGM, has been associated with increased CGM use in both the DPV Initiative and T1DX Registry. Increased rates of CGM use were evident across all age ranges, but especially in the youngest children where CGM usage rates increased dramatically. As penetrance of this technology is lowest in adolescents, a group noted to have the highest mean HbA1c; strategies to engage this cohort of youth in adoption and long‐term use of CGM are needed. Additionally, reimbursement practices for CGM remains quite complex and varies across countries, states, regions and insurance companies, so advocacy efforts for insurance coverage are needed especially in the United States where coverage by Medicaid programs varies greatly across states.

A majority of pediatric patients are now utilizing insulin pumps for diabetes management in both DPV and T1DX registries in 2016. CGM use has increased over the last 5 years, still less than half of pediatric patients are utilizing these devices. This is especially concerning in light of the challenges in achieving glycemic targets (HbA1c \< 7.5% \[\<58 mmol/mol\]) in pediatrics. Further analysis is needed to determine the reasons for low frequency of CGM use including whether reimbursement or cost of CGM may be a barrier to use. Robust clinical protocols, quality improvement and research efforts to optimize real‐time CGM use are essential to ensuring durability of CGM use, facilitating automation of insulin delivery and improving glycemic outcomes.[9](#pedi12711-bib-0009){ref-type="ref"}
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**AppendixS1**. A list of the T1D Exchange Clinic Network sites with participating principal investigators (PI), co‐investigators (I) and coordinators (C) ordered by the number of participants recruited per site as of June 1, 2017.
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Click here for additional data file.
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